A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042 an anti-PD-1 Monoclonal Antibody in Patients with Advanced Solid Tumors
Brief description of study
The main goal of the cohort expansion study is to evaluate the antitumor activity of an investigational drug, TSR-042 (a PD-L1 and PD-L2 receptor blocking agent) in patients with recurrent and advanced endometrial cancer.
Clinical Study Identifier: s16-01027
ClinicalTrials.gov Identifier: NCTs16-01027
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
